Management

DBV Technologies is led by an experienced management team with a proven track record of developing scientific and medical products and bringing them to market. DBV employs a highly trained R&D team that continues to refine the core technology and identify new opportunities for product development.

Dr Pierre-Henri Benhamou
Chief Executive Officer
Details

Dr. Pierre-Henri Benhamou is a co-founder and Chief Executive Officer of DBV Technologies. He is a former Interne des Hôpitaux and former Chief of Clinic. He is specialized in pediatric gastroenterology and has held a number of senior clinical positions after studying Pediatrics in Paris and Amiens. In 1989 Dr. Benhamou created the Centre for Digestive Exploration of Infants at the Surgical Clinic in Boulogne-Billancourt – one of the most important specialized pediatric centres in Europe. Dr. Benhamou received the Prize for Innovation from the Altran Foundation in 2003 for his work on the development of patch tests for the diagnosis of cow’s milk proteins allergy. Within the company Dr. Benhamou currently holds the positions of Chief Executive Officer and Chief Scientific Officer.

Mr. Bertrand Dupont
Chief Technical Officer
Details

Mr. Bertrand Dupont is DBV Technologies’ co-founder and Chief Technology Officer (CTO). Prior to co-founding DBV Technologies, Mr. Dupont qualified as an engineer from the école Nationale Supérieure des Arts et Métiers in Paris and went on to pursue a career in teaching and consultancy. From 1996, Mr. Dupont began applying his knowledge and experience of mechanical engineering to biomedical research and from 2000 was central to the development of VIASKIN^® patch technology and application system. As CTO, Mr. Dupont leads the development of the VIASKIN^® technology across its current and future biomedical applications.

Mr. David Schilansky
Chief Financial Officer
Details

David Schilansky has joined DBV Technologies, as Chief Financial Officer and as such, supervise all Financial activities of the Group as well as partnerships and Business Development initiatives. David is a member of the Executive Committee. Prior to joining DBV Technologies, David Schilansky was Deputy CFO of Ipsen, that he joined in 2006. David was in charge of major functions within the Finance & Administrative Department, and participated in several external growth transactions as well as the creation of an Investor Relations department. In 2011, David also served as interim CFO and member of the Executive Committee. Prior to joining Ipsen, David spent three years at UBS Warburg, in Mergers & Acquisitions, and three years at Thomson as Investor Relations’ Officer. David graduated from paris Dauphine University is a post graduate of Imperial College London.

Mr. Charles Ruban
Chief Development Officer
Détails

Prior to joining DBV Technologies, Charles Ruban was Senior VP, Product Development at Stallergènes, member of the Executive Committee. After a 9 years european experience in management consulting for Europroup, Charles has spent 10 years at Stallergènes. He started heading Supply Chain management, and evolved as R&D Program Director before moving to his leadership role. Charles graduated from Ecole Centrale de Lyon, concluded his Master of Science in Biomedical Engineering at Harvard-M.I.T. Division of Health Sciences and Technology and holds an ExecutiveMBA from INSEAD.

Dr Laurent Martin
Regulatory Affairs Director
Details

Dr. Laurent Martin joined DBV Technologies as Regulatory Affairs Director. He previously worked at Orphan Europe, a Company specialized in marketing orphan drugs, where his responsibilities were divided between Regulatory Affairs and Quality Assurance. At DBV Technologies, Dr. Martin will use his international regulatory affairs experience and knowledge of the pharmaceutical industry gained at Galderma, Fournier and Guerbet to co-ordinate worldwide registration of DBV Technologies pharmaceutical products. Dr. Martin holds an MBA from IAE Paris Sorbonne and received his Masters in Public Health Law from the Faculty of Sceaux, France. Dr. Martin graduated as a pharmacist at the University Rene Descartes, Paris, France.

Dr Wence Agbotounou
Chief Clinical Trial Officer
Details

Dr. Wence Agbotounou joined DBV Technologies as the Chief Clinical Trial Officer. His previous experience includes positions in many leading CROs such as Quintiles and PRA International. As a Global Project Manager and Project Director, he launched and successfully managed global clinical trials for big and mid-size pharmaceutical companies, including several immunotherapy trials. Dr. Agbotounou graduated with a PhD in Pharmacology from the University Pierre et Marie Curie in Paris, France. He holds an MBA from ESCP, Europe, a European Management School based in Paris, France.